
edited by Bhanu P. Jena and Douglas J. Taatjes

NANOCELL BIOLOGY Multimodal Imaging in Biology and Medicine





edited by Bhanu P. Jena and Douglas J. Taatjes

NANOCELL BIOLOGY Multimodal Imaging in Biology and Medicine

Published by

Pan Stanford Publishing Pte. Ltd. Penthouse Level, Suntec Tower 3 8 Temasek Boulevard Singapore 038988

Email: editorial@panstanford.com Web: www.panstanford.com

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library.

NanoCellBiology: Multimodal Imaging in Biology and Medicine

Copyright © 2014 Pan Stanford Publishing Pte. Ltd.

All rights reserved. This book, or parts thereof, may not be reproduced in any form or by any means, electronic or mechanical, including photocopying, recording or any information storage and retrieval system now known or to be invented, without written permission from the publisher.

For photocopying of material in this volume, please pay a copying fee through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA. In this case permission to photocopy is not required from the publisher.

ISBN 978-981-4411-79-0 (Hardcover) ISBN 978-981-4411-80-6 (eBook)

Printed in the USA

NANOCELLBIOLOGY

Dedicated to my students who have made my journey through science greatly rewarding and filled with excitement.

-Bhanu P. Jena

此为试读,需要完整PDF请访问: www.ertongbook.com

Preface

Just as the ultimate goal in biology is to unravel the structure and dynamics of a living cell at the atomic level, so is the major challenge in medicine to treat and ameliorate diseases noninvasively. This requires the targeting, imaging, and destruction of pathogen and diseased cells without harm to healthy cells and tissues. On close examination, however, the above two objectives seem inseparable, and an understanding of cellular structure-function is invaluable to the success in drug design, development, and therapy. Similarly, our understanding of the fundamental life processes or the treatment of diseases greatly relies on key technological advancements, an extraordinary example being the invention of the atomic force microscope (AFM), which gave birth to nanotechnology. In this book, applications of the AFM in the discovery of a new cellular structure, the "porosome," in our understanding of cellular and molecular processes, and in the design and development of novel modalities in disease detection and treatment are presented. Similarly, novel approaches to understand molecular evolution, and the surprising involvement of mRNA nanomachines in disease processes, are also discussed.

Secretion is a fundamental cellular process involved in neurotransmission, and the release of hormones and digestive enzymes. Impaired secretion results in diseases such as diabetes and neuronal or digestive disorders. In Chapter 1, a brief commentary is provided on a new cellular structure, the "porosome," a secretory nanomachine discovered nearly 16 years ago and demonstrated to be the universal secretory portal in cells. In Chapters 2 and 3, porosomes in hair cells and in brain neurons of different species of mammals are presented. The porosome discovery has clarified our understanding of the generation of partially empty secretory vesicles in cells following secretion, providing a molecular understanding of the process, and resulting in a paradigm-shift in our understanding of cell secretion. In Chapter 4, the biogenesis

of secretory vesicles and their distribution and dynamics, so critical to cell secretion, is elaborated. In Chapter 5, the authors introduce the reader to the application of the AFM in investigating protein assembly, biomineralization, and biomolecular interactions. Similarly, in Chapter 6, using a combination of AFM, fluorescence microscopy, and circular dichroism spectroscopy, the authors provide an insight into amylin aggregation, trafficking, and toxicity. These studies will provide the basis for the treatment of amyloid pathology such as amyloid deposits in type 2 diabetes. As in the case of amyloid pathophysiology, the utilization of the AFM to investigate novel treatment strategies is also in the advance. In Chapter 7, the use of AFM to investigate an autoimmune thrombotic conditions known as the antiphospholipid syndrome is discussed. Biological function of proteins resides in their threedimensional shape, and an understanding of this three-dimensional protein structure is also essential for the design and development of drugs to regulate the protein. In Chapter 8, a novel approach to determine the molecular evolution of proteins using antibodies as nanoprobes, is presented. Similarly, the interaction of molecules and their assembly and diassembly within cells dictate cellular responses. In cardiac arrest and stroke, brain ischemia resulting from reduced blood flow to the brain leads to brain injury and even death. In Chapter 9, the authors describe a unique buildup of nucleoprotein granules of unknown composition in ischemic brain neurons. An understanding of the structure and composition of these granules promises a new approach for the treatment of brain ischemia. Magnetic nanoparticles have begun to show great promise in targeting, imaging, and destruction of pathogen and diseased cells without harm to healthy tissues. In Chapter 10, the emergence of magnetic nanoparticles for transformative application in medicine and therapy is discussed. Nano gene therapies using nanopolymers and virus-based therapy are rapidly being developed. In Chapter 11, AFM has been used to study DNA release dynamics from biopolymer-based nanosystems. New and novel methods and approaches to evaluate and image both biological and non-biological material are constantly in progress. In Chapter 12, the final chapter, the rapidly developing application of electrical impedance spectroscopy in biology is discussed. It is clear from the studies and findings discussed in this

book that the development of nanotechnology and its use in unraveling fundamental biological principles are key to medical breakthroughs and in the effective diagnosis and treatment of diseases.

> Bhanu P. Jena **Douglas J. Taatjes**

Contents

| Pref | ace | | | : | xvii |
|------|------|--------------------|------------|---|------|
| 1. | | somes– ef Essay | | versal Secretory Portals in Cells: | 1 |
| | Bhan | u P. Jena | | | |
| 2. | | Hair Cel | | e: Molecular and Synaptic | 17 |
| | Denn | is G. Dre | scher | | |
| | 2.1 | Introd | uction | | 17 |
| | 2.2 | Metho | ds | | 19 |
| | 2.3 | SNARI | Es | | 20 |
| | 2.4 | The Po | orosome | | 24 |
| | 2.5 | Discov | ery of the | e Hair-Cell Porosome | 25 |
| | 2.6 | Conclu | usions an | d Future Studies | 29 |
| 3. | | | | me Complex in Mammalian Brain: n Microscopy | 39 |
| | | | | nda J. Japaridze, Mariam G. Qsovreli, G. Surmava, and Tamar G. Lordkipanidze | |
| | 3.1 | Introd | luction | | 40 |
| | 3.2 | Neuro | nal Poros | some in Rat, Cat, and the Dog Brains | 42 |
| | | 3.2.1 | Materia | and Methods | 42 |
| | | | 3.2.1.1 | Animals and experimental design | 42 |
| | | | 3.2.1.2 | Electron microscopic examination | 43 |
| | | | 3.2.1.3 | $Morphometric\ analysis\ of\ porosome$ | |
| | | | | diameter and depth | 43 |
| | | | 3.2.1.4 | Statistical analyses | 46 |
| | | 3.2.2 | Results | | 46 |

| | 3.3 | Stres | | ne Rat Brain: Effect of Hypokinetic | F.0 |
|----|------------|--------|-------------|---|-----|
| | | 3.3.1 | | al and Methods | 50 |
| | | 5.5.1 | 3.3.1.1 | Animals and experimental design: | 51 |
| | | | 5.5.1.1 | simulation of hypokinesia | 51 |
| | | | 3.3.1.2 | EM examination | 51 |
| | | | 3.3.1.3 | Morphometric analysis of porosome | - |
| | | | | diameter and depth | 52 |
| | | | 3.3.1.4 | Statistical analyses | 52 |
| | | 3.3.2 | Results | | 52 |
| | 3.4 | Discu | ıssion | | 56 |
| | 3.5 | Conc | lusion and | d Future Studies | 58 |
| 4. | | | | tion Suggests Mechanism: The Case | |
| | | | | nd Elimination as a Fusion | |
| | | o-Mach | | | 63 |
| | | Hamme | l and Isaac | Meilijson | |
| | 4.1 | | duction | | 63 |
| | 4.2 | | | anagement of the Inventory of | |
| | 12 | Granı | | D | 67 |
| | 4.3 4.4 | | | nventory Represent "New Old Stock"? unication: Evoked State Yields | 69 |
| | 4.4 | | nation | unication: Evoked State Yields | 73 |
| _ | | | | | /3 |
| 5. | | | | mbly, Biomineralization, eractions by Atomic Force Microscopy | or. |
| | | | | s J. De Yoreo | 85 |
| | | | | s J. De Toreo | |
| | 5.1 | | duction | Forton In | 86 |
| | 5.2 | | rials and M | | 87 |
| | | 5.2.1 | | on of AFM | 87 |
| | | | 5.2.1.1 | Contact mode | 88 |
| | | | 5.2.1.2 | Tapping mode | 88 |
| | | 5.2.2 | | Force spectroscopy | 90 |
| | | J.L.L | Convolu | Observed in AFM Images: Tip | 91 |
| | | 5.2.3 | Protein I | | 91 |

| | | 5.2.3.1 | Determining protein particle size by using calibration curves of protein | |
|------|----------|------------|--|-----|
| | | | heights versus molecular weights | 95 |
| | 5.2.4 | Experim | ental Design of in situ AFM | |
| | | Investig | ation of Macromolecular and | |
| | | Biomine | ral Crystal Growth | 98 |
| 5.3 | | | gation of the Pathway for | |
| | Recon | nbinant H | uman Prion Protein Aggregation | 100 |
| | 5.3.1 | Seed For | rmation of HurPrP ^C | 101 |
| | 5.3.2 | Growth | of β-Oligomers and Non-Fibrillar | |
| | | Aggrega | tes | 103 |
| 5.4 | | | e Calcium Oxalate Monohydrate | |
| | Crysta | | by Biomolecules | 106 |
| | 5.4.1 | - | ium Shape of Pure COM Crystal and | |
| | | Its Grow | | 106 |
| | 5.4.2 | | on of Calcium Oxalate Monohydrate | |
| | | 2 | Growth by Biomolecules at the | 100 |
| | | 5 //5/07 | eter and Micrometer Scales | 108 |
| | | | Citrate | 108 |
| | | | Osteopontin | 110 |
| | | | Tamm-Horsfall Protein | 112 |
| 5.5 | | - | Amelogenin Protein C-Terminal | |
| | 0 | | ing to Hydroxyapatite | 114 |
| 5.6 | Concl | usions ar | nd Future Studies | 117 |
| High | -Resolu | ution Imag | ging of Amylin Aggregation and | |
| Inte | rnalizat | ion in Par | ncreatic Cells: Implications in Health | |
| and | Disease | 9 | | 131 |
| Saur | abh Trik | kha, Sangh | amitra Singh, and Aleksandar M. Jeremic | |
| 6.1 | | | Aggregation in Etiology of Type-2 | 132 |
| | | etes Melli | | |
| 6.2 | | | pproaches to Analyze Conformational linetics of Amylin Aggregation in | |
| | Solut | _ | micues of minymirings regarded in | 133 |
| 6.3 | | | on Force Imaging of Amylin | |
| 0,0 | _ | egation | y | 135 |

6.

| | 6.4 | _ | 1,50 | le of Membranes in Amylin | |
|----|---------------|----------------------|--------------------|--|-----|
| | | | | on and Aggregation | 142 |
| | 6.5 | | | ar Assembly of Amylin on Neutral, | |
| | | | | ipid Raft Membranes | 143 |
| | 6.6 | | | of Anionic Lipids and Cholesterol | |
| | | | oramolec oranes | ular Assembly of Amylin on Planar | |
| | 6.7 | | | on Microscopy of Amylin Azamatian | 144 |
| | 0.7 | | | on Microscopy of Amylin Aggregation ation in Cells | 148 |
| 7. | Antio Nove | coagula | nt Shield | ts in a Two-Dimensional Crystal in the Antiphospholipid Syndrome: itegies Assessed by Atomic Force | 157 |
| | | las J. Ta acob H. | | ony S. Quinn, Xiao-Xuan Wu, Han-Mou Tsai, | |
| | 7.1 | Introd | luction | | 158 |
| | 7.2 | Mater | ials and I | Methods | 159 |
| | 7.3 | Result | S | | 160 |
| | | 7.3.1 | | sessment of the Modulation of APS by | |
| | | | | cological and Molecular Intervention | 160 |
| | | | 7.3.1.1 | Hydroxychloroquine-mediated | |
| | | | 7040 | increase of AnxA5 binding | 160 |
| | | | 7.3.1.2 | Reversal of AnxA5 resistance with "patch treatment" for AnxA5 | |
| | 7.4 | 0 1 | | defects | 164 |
| | 7.4 | Conclu | isions an | d Outlook | 168 |
| 8. | of An | cestral | Conform | Study Molecular Evolution: Detection ation Hidden in Present-Day Proteins nostructure Probes | 173 |
| | Jian-P | ing Jin | | | |
| | 8.1 | Evolut | ion Is Da | ta: Can We Get Fossil-Like | |
| | | Inform Protein | | the Ancestor of a Present-Day | 174 |
| | | Antibo Probes | | hree-Dimensional Nanostructure | 175 |

| | 8.3 | - | e-Linked Immunosorbant Assay for Protein e Analysis | 175 | | |
|----|--|------------------------|---|-----|--|--|
| | 8.4 | - | ling Studies of Troponin Subunits | 176 | | |
| | 8.5 | | ectional Immunological Cross-Reactivity rclonal Anti-TnI and Anti-TnT Antibodies | 177 | | |
| | 8.6 | | ion of Evolutionarily Suppressed TnI-Like e Structures in TnT | 178 | | |
| | 8.7 | | ion of Evolutionarily Suppressed Fast ke Epitope Structurein Cardiac TnT | 179 | | |
| | 8.8 | | tion of Evolutionarily Suppressed Cardiac | | | |
| | | TnT-Li | ke Epitope Structure in Slow TnT | 179 | | |
| | 8.9 | Implic | ations | 180 | | |
| | 8.10 | Applic | ations | 182 | | |
| | 8.11 | Summ | ary and Perspectives | 182 | | |
| 9. | mRNA Nanomachines and Stress Reprogramming Following Brain Ischemia | | | | | |
| | Dona Moni | ld J. DeG que K. Le | racia, Jill T. Jamison, Manupreet Chawla, ewis, Michelle Smith, and Jeffery J. Szymanski | | | |
| | 9.1 | Introd | luction | 190 | | |
| | 9.2 | The Co | omplexity of mRNA Regulation | 192 | | |
| | | 9.2.1 | mRNA Binding Proteins and mRNAs | 192 | | |
| | | 9.2.2 | mRNA Ribonucleoprotein Complexes | 193 | | |
| | | 9.2.3 | The Ribonomic Network and the Central | | | |
| | | | Dogma | 195 | | |
| | 9.3 | Brain | Ischemia | 196 | | |
| | | 9.3.1 | What Is Ischemia? | 196 | | |
| | | 9.3.2 | Clinical Manifestations of Brain Ischemia | 197 | | |
| | | 9.3.3 | The Holy Grail of Neuroprotection | 198 | | |
| | 9.4 | Molec | cular Understanding of Brain Ischemia | 199 | | |
| | | 9.4.1 | Neuronal Cell Biology of the Ischemic Period | 200 | | |
| | | 9.4.2 | Neuronal Cell Damage in the Reperfusion Period | 200 | | |

| | 9.4.3 | Neurons | | | | |
|------|--|--|-----|--|--|--|
| 9.5 | Trans | slational Control in Post-Ischemic Neurons | 201 | | | |
| 7.5 | and Injured Cells | | | | | |
| 9.6 | | Persistent TA in Vulnerable Neurons | | | | |
| | 9.6.1 | | 205 | | | |
| | 9.6.2 | | 207 | | | |
| | 9.6.3 | A series of the series in the series of the | 209 | | | |
| | 9.6.4 | The state of the s | 210 | | | |
| 9.7 | Stress | s Granules and Brain Ischemia and | 210 | | | |
| | | rfusion | 211 | | | |
| | 9.7.1 | The Fuzzy Border between Sequestration | | | | |
| | | and Regulation | 211 | | | |
| | 9.7.2 | Stress Granules | 211 | | | |
| | 9.7.3 | Detecting and Quantifying Stress Granules | | | | |
| | | in Brain | 213 | | | |
| | 9.7.4 | Stress Granules in Brain I/R | 215 | | | |
| | 9.7.5 | Other SG Antigens | 219 | | | |
| 9.8 | mRNA | A Granules in Reperfused Neurons | 221 | | | |
| | 9.8.1 | mRNA Granules | 222 | | | |
| | 9.8.2 | mRNA Granules Time Course and Correlation | 1 | | | |
| | | with Translation Arrest in 2VO/HT | 224 | | | |
| | 9.8.3 | Colocalization of Proteins with mRNA | | | | |
| | | Granules | 227 | | | |
| | 9.8.4 | HuR Colocalization with mRNA Granules | 229 | | | |
| 9.9 | Behavior of mRNA Granules under Other Conditions | | | | | |
| | | | 230 | | | |
| | 9.9.1 | 2VO/HT Model: Effect of Ischemia Duration on mRNA Granules | 220 | | | |
| | 9.9.2 | Focal Cerebral Ischemia Effect on mRNA | 230 | | | |
| | 7.7.4 | Granules | 231 | | | |
| | 9.9.3 | Effect of Endothelin-1 on mRNA Granules | 234 | | | |
| | 9.9.4 | Effect of Cycloheximide and Puromycin on | 207 | | | |
| | | mRNA Granules | 235 | | | |
| 9.10 | Summary of mRNA Granules 2. | | | | | |

| 10.1 | 9 Synthe | SIS | 287 | | |
|----------|-------------|------------------------------------|-----|--|--|
| | 10.19.2 | 1 Co-Precipitation | 288 | | |
| | 10.19.2 | 2 Hydrothermal Synthesis | 289 | | |
| | 10.19.3 | 3 Microemulsion | 290 | | |
| | 10.19.4 | 4 Coating | 291 | | |
| | | 10.19.4.1 Organic coatings | 291 | | |
| | | 10.19.4.2 Inorganic coatings | 292 | | |
| 10.20 |) Functio | onal Groups | 293 | | |
| 10.21 | Biomed | lical Applications | 294 | | |
| | 10.21.1 | l Magnetic Hyperthermia | 294 | | |
| | 10.21.2 | 2 Controlled Drug Release | 296 | | |
| | 10.21.3 | B Magnetic Resonance Imaging | 297 | | |
| | 10.21.4 | Gene Delivery | 299 | | |
| | 10.21.5 | Nanoparticle Endocytosis | 299 | | |
| 10.22 | ? Conclus | sions | 301 | | |
| 11. Aton | nic Force I | Microscopy Imaging of DNA Delivery | | | |
| | Nanosystems | | | | |
| Yi Zo | u, David Ou | ipicky, and Guangzhao Mao | | | |
| 11.1 | Introdu | action | 321 | | |
| 11.2 | Materia | als and Methods | 324 | | |
| | 11.2.1 | Materials | 324 | | |
| | 11.2.2 | Polyplex Preparation | 325 | | |
| | 11.2.3 | LbL Preparation | 325 | | |
| | 11.2.4 | AFM Imaging | 325 | | |
| 11.3 | Results | and Discussion | 326 | | |
| | 11.3.1 | Polyplex Self-Assembly | 326 | | |
| | 11.3.2 | Cooperative DNA Release | | | |
| | | vs. Non-Cooperative DNA Release | 328 | | |
| | 11.3.3 | A Proposed Disassembly Route for | | | |
| | | Bioreducible Polyplexes | 329 | | |
| | 11.3.4 | LbL Film Assembly | 330 | | |
| | 11.3.5 | LbL Film Disassembly | 330 | | |
| | 11.3.6 | Cross-Linking of LbL Films | 334 | | |
| 11.4 | Summar | 335 | | | |

| 12. | Impedance Spectroscopy for Characterization of Biological | | | | | |
|-------|---|--------------|---|--------------------------------|--------------------------|--|
| | Funct | | | | | |
| | Brian | C. Riggs, Jo | anet L. Paluh, G. E. Plopper, and Douglas B. Chrise | | | |
| | 12.1 | Introdu | ction | tion | | |
| | | 12.1.1 | History | | 343 | |
| | | 12.1.2 | General I | nformation | 344 | |
| | | 12.1.3 | Experime | Experimental Setup | | |
| | | 12.1.4 | More Tha | n Just Equipment | 345 | |
| | | 12.1.5 | Application | ons | 346 | |
| | 12.2 | Material | ls and Metl | nods | 347 348 350 352 | |
| | | 12.2.1 | Plotting t | he Data | 348 | |
| | | 12.2.2 | Building a | an Equivalent Circuit Model | 350 | |
| | | 12.2.3 | Validating | g and Improving the Model | 352 | |
| | | 12.2.4 | Physical I | Meaning of Our Parameters | 354 | |
| | 12.3 | Applicat | ons | | | |
| | | 12.3.1 | Fundame | ntal Biology | 356 | |
| | | | 12.3.1.1 | Cell adhesion | 357 | |
| | | | 12.3.1.2 | Cell mobility | 358 | |
| | | | 12.3.1.3 | Cell signaling | 358 | |
| | | 12.3.2 | Healthcar | re Applications | 358 | |
| | | | 12.3.2.1 | Hepatitis-B DNA sensors | 359 | |
| | | | 12.3.2.2 | Cancer metastasis | 360 | |
| | | 12.3.3 | In the Fie | eld: Environmental Monitoring | 361 | |
| | | | 12.3.3.1 Detection of environmental pollutants | | 361 | |
| | | | 12.3.3.2 | Detection of foreign pathogens | 362 | |
| | 124 | Conclus | | | | |
| | 12.4 Conclusion | | | | | |
| Index | | | | 371 | | |